Since the combination of IRAK1/4 inhibitor and imatinib attenuates PD-L1 expression on CML LSCs, the combination also induces T cell antitumor immunity in addition to its proapoptotic activity. The gene discussed is CD274; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.